Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer

Annals of Surgical Oncology

Volumn 18, Issue 10, 2011, Pages 2851-2857

  Meyers, Michael O ^a   Klauber Demore, Nancy ^a   Ollila, David W ^a   Amos, Keith D ^a   Moore, Dominic T ^a   Drobish, Amy A ^a   Burrows, Emily M ^a   Dees, E Claire ^a   Carey, Lisa A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; FOLLOW UP; HUMAN; LOCOREGIONAL RECURRENCE; MAJOR CLINICAL STUDY; MASTECTOMY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052717931     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1665-8     Document Type: Article

References (20)

1. AM Chen, et al. 2004 Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience J Clin Oncol 22 12 2303 2312 15197191 10.1200/JCO.2004.09.062 (Pubitemid 41115386)
2. WG Cance, et al. 2002 Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival Ann Surg 236 3 295 302 12192316 10.1097/00000658-200209000-00006 discussion 302-3 (Pubitemid 34971339)
3. G Bonadonna, et al. 1998 Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J Clin Oncol 16 1 93 100 9440728 1:STN:280:DyaK1c7gtFKkug%3D%3D (Pubitemid 28041584)
4. CK Anders LA Carey 2009 Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer Clin Breast Cancer 9 Suppl 2 S73 S81 19596646 10.3816/CBC.2009.s.008 1:CAS:528:DC%2BD1MXptlWgt7w%3D
5. SH Dairkee L Puett AJ Hackett 1988 Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue J Natl Cancer Inst 80 9 691 695 2453676 10.1093/jnci/80.9.691 1:STN:280: DyaL1c3jtVGjtA%3D%3D
6. CM Perou, et al. 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
7. R Rouzier, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 5678 5685 16115903 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
8. T Sorlie, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
9. T Sorlie, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 14 8418 8423 12829800 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
10. C Sotiriou, et al. 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 18 10393 10398 12917485 10.1073/pnas.1732912100 1:CAS:528: DC%2BD3sXntFynsrk%3D (Pubitemid 37071889)
11. TO Nielsen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 16 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
12. LA Carey, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 21 2492 2502 16757721 10.1001/jama.295.21. 2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D (Pubitemid 43854964)
13. BG Haffty, et al. 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 36 5652 5657 17116942 10.1200/JCO.2006.06.5664 (Pubitemid 46631305)
14. CU Ihemelandu, et al. 2008 Treatment and survival outcome for molecular breast cancer subtypes in black women Ann Surg 247 3 463 469 18376191 10.1097/SLA.0b013e31815d744a
15. PL Nguyen, et al. 2008 Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 14 2373 2378 18413639 10.1200/JCO.2007.14.4287
16. Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34. (Pubitemid 47219710)
17. Carey LA, et al. Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials. Proc AACR/CTRC San Antonio Breast Cancer Symposium, 2009. Abstract 2014.
18. JS Parker, et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 8 1160 1167 19204204 10.1200/JCO.2008.18. 1370
19. Yu TK, et al. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Proc AACR/CTRC San Antonio Breast Cancer Symposium, 2009. Abstract 957.
20. M Kyndi, et al. 2008 Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group J Clin Oncol 26 9 1419 1426 18285604 10.1200/JCO.2007.14.5565 1:CAS:528:DC%2BD1cXkslKqs7c%3D